Havel, Jonathan J. http://orcid.org/0000-0003-0951-510X
Chowell, Diego
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Article History
First Online: 12 February 2019
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from An2H, AstraZeneca, Bristol-Myers Squibb, Eisai, Illumina and Pfizer. T.A.C. has served as an adviser for An2H, Bristol-Myers Squibb, Eisai, Illumina and MedImmune. T.A.C. holds ownership of intellectual property on using tumour mutation burden to predict immunotherapy response, with a pending patent, which has been licensed to Personal Genome Diagnostics. J.J.H.’s spouse is a full-time employee of Regeneron Pharmaceuticals.